NCI-H358 is a tumorigenic cell line that was established in 1981 from the bronchiole tissue of a male with bronchioalveolar carcinoma. NCI-H358 cells display adherent cultural properties in vitro and an epithelial morphology. NCI-H358 produces lung surfactant associated protein A (SP-A) and expresses the RNA of SP-A. NCI-H358 cells are suitable transfection hosts, and Altogen Biosystems offers a NCI-H358 transfection reagent to transfect NCI-H358 cells. The NCI-H358 cell line can be used to study lung cancer and develop therapeutics.
The NCI-H358 cell line was first established in 1981 from removed bronchiole tissue of a patient suffering from bronchioalveolar carcinoma (lung cancer). The tissue was removed from the patient prior to any administered chemotherapy treatments. The NCI-H358 cell line has a doubling time of about 38 hours, it has detectable Clara cells and is an exceptional transfection host. This cell line is also a great candidate for in vitro research studies, such as those at Altogen Biosystems . T he in vitro research models are helpful to solving lung cancer and useful as transfection hosts. Transfection Reagent for NCI-H358 Cells (Bronchioalveolar Cells, CRL-5807)
Comments
Post a Comment